Advances in thalidomide therapy for idiopathic myelofibrosis / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 651-653, 2009.
Article
in Chinese
| WPRIM
| ID: wpr-301633
ABSTRACT
Idiopathic myelofibrosis a Philadelphia-negative chronic myeloproliferative disorder. Potentially curative therapies, such as stem-cell transplantation, are reserved only for a minority of patients. Currently palliative therapies such as androgen and hydroxycarbamide are commonly used but with poor results. Thalidomide has anti-angiogenic effect and also can inhibit cytokines, and therefore plays a certain role in the treatment of a subset of idiopathic myelofibrosis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thalidomide
/
Treatment Outcome
/
Angiogenesis Inhibitors
/
Therapeutic Uses
/
Drug Therapy
/
Primary Myelofibrosis
/
Immunosuppressive Agents
Limits:
Humans
Language:
Chinese
Journal:
Acta Academiae Medicinae Sinicae
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS